Zusammenfassung
2-[l8F]-2-desoxy-D-glukose (2-[l8F]-FDG) ist die am häufigsten eingesetzte Substanz unter den PET-Ra-diopharmaka in Europa mit mehr als 200 Applikationen pro Woche (Meyer et al. 1995). Die in der Literatur beschriebenen Untersuchungen wurden mit unterschiedlichen 2-[l8F]-FDG-Präparaten durchgeführt, die sich nur unwesentlich voneinander unterscheiden. Für die Bewertung der klinischen Daten sind diese Unterschiede unerheblich.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Literatur
Baudot P, Jaque M, Robin M (1977) Effect of a diazo-polyoxa-macroobicyclic complexing agent on the urinary elimination of lead in lead-poisened rats. Toxicol Appl Pharmacol 41: 113–115
Baumann M, Schäfer E, Grein H (1984) Short term studies with the cryptating agent hexaoxa-diaza-bicyclo-hexacosane in rats. Arch Toxicol 55 [Suppl 7]: 427–429
Dowd MT, Chin-Tu C, Wendel MJ, Faulhaber PJ, Cooper MD (1991) Radiation dose to the bladder wall from 2-(l8F) fluoro-2-de-soxy-D-glucose in adult humans. J Nucl Med 32: 707–712
European Pharmacopoeia (1996) Radiopharmaceutical preparations, pp 1424–1433
Gallagher BM, Ansari A, Atkins H et al. (1977) Radiopharmaceuticals XXVII. 18F-labeled 2-desoxy-2-fluoro-D-glucose as a radiopharmaceutical for measuring regional myocardial glucose metabolism in vivo: tissue distribution and imaging studies in animals. J Nucl Med 18: 990–996
Gallagher BM, Fowler JS, Gutterson NI, MacGregor RR, Wan CN, Wolf AP (1978). Metabolic trapping as a principle of radiopharmaceutical design: some factors responsible for the biodistribution of 2-Deoxy-2-[l8F]fluoro-D-glucose. J Nucl Med 19: 1154–1161
Hamacher K, Coenen HH, Stöcklin G (1986) Efficient stereospecific synthesis of no-carrier-added 2-[l8F] fluoro-2-deoxy-D-glucose using aminopolyether supported nucleophilic substitution. J Nucl Med 27: 235–238
Mejia AA, Nakamura T, Mastoshi I, Hatazawa J, Masaki M, Shoichi W (1991) Estimation of absorbed doses in humans due to intravenous administration of fluorine-l8F-fluorodeoxyglucose in PET studies. J Nucl Med 32: 699–706
Meyer G-J, Coenen HH, Waters SL et al. (1993) Quality assurance and quality control of short-lived radiopharmaceutikals for PET. In: Stöcklin and Pike (eds) Radiopharmaceuticals for PET. Kluwer, Amsterdam, pp 91–150
Meyer GJ, Waters SL, Coenen H H., Luxen A, Maziere B, Langström B (1995) PET radiopharmaceuticals in Europe: current use and data relevant for the formulation of summaries of product characteristics (SPCs). Eur J Nucl Med 22/12: 1420–1432
Oehr P, Ruhlmann J, Rink H (1989) 18F-FDG Transport: Abhängigkeit von Glucosekonzentration und Strahlendosis. Nuklearmedizin 37: A68
Reivich M, Kühl D, Wolf A et al. (1979). The [l8F] fluorodeoxyglu-cose method for the measurement of local cerebral glucose utilization in man. Circ Res 44: 127–137
Som P, Atkins HL, Bandoypadhyay D, Fowler JS et al. (1980) A fluorinated glucose analog, 2-fluoro-2-deoxy-D-glucose (F-18): nontoxic tracer for rapid tumor detection. J Nucl Med 21: 670–675
United States Pharmacopeia, USP (1995) Fludeoxyglucose F18 Injections. USP 23: 674
Woosley RL, Kim YS, Huang KC (1970) Renal tubular transport of 2-deoxy-D-glucose in dogs and rats. J Pharmacol Exp Ther 173: 13–20
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1998 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Ruhlmann, J., Oehr, P. (1998). Radiopharmazie, Toxizität und Strahlendosis. In: Rühlmann, J., Oehr, P., Biersack, HJ. (eds) PET in der Onkologie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-09242-2_2
Download citation
DOI: https://doi.org/10.1007/978-3-662-09242-2_2
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-662-09243-9
Online ISBN: 978-3-662-09242-2
eBook Packages: Springer Book Archive